Systemic sclerosis portends increased risk of conduction and rhythm abnormalities at diagnosis and during disease course: A US population-based cohort
Yasser Radwan(Mayo Clinic), Ashima Makol(Mayo Clinic), Rekha Mankad(Mayo Clinic in Arizona), Eric L. Matteson(Mayo Clinic in Arizona), Reto Kurmann(Carol Davila University of Medicine and Pharmacy), Cynthia S. Crowson(Mayo Clinic in Florida), Kenneth J Warrington(Mayo Clinic in Arizona), Thomas G. Osborn(Mayo Clinic in Arizona), Avneek Singh Sandhu(Mayo Clinic in Arizona), Edward El‐Am(Mayo Clinic in Arizona)
Cited by 9
Related Papers
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis Care & Research|2015|1.1k